The State Of Materiovigilance: Capability Gaps, Technology Momentum, And Outsourcing Readiness

By Meredith Landry, Managing Editor Of Custom Content, Citeline

As drug-device combination products, diagnostics, and digital therapeutics expand, pharma and biotech companies are facing growing materiovigilance demands. Based on IQVIA’s 2025 Materiovigilance and Technology Adoption survey, this report explores how organizations are addressing gaps in safety expertise, processes, and technology while adapting to evolving global regulations. It also examines the increasing role of outsourcing, AI-driven solutions, and strategic partnerships in supporting compliant, scalable postmarket safety programs. Download the report to learn how industry leaders are preparing for the future of combination product oversight.